Literature DB >> 19618128

[Complication after subacute cervical lymphadenitis].

A Knopf1, E Q Scherer.   

Abstract

A 56-year-old female patient presented with a 3-day-old odynophagy and a painful swelling in the left side of the neck. In addition to reddening and swelling of the left side of the neck, which was painful on palpation, leukocytosis and increased C-reactive protein (CRP) and fibrinogen levels were also found. Enlarged lymph nodes along the left vessel-nerve sheath and thrombosis of the internal jugular vein were detected by sonography and computed tomography. The patient could be identified as a heterozygote carrier of the factor V Leiden mutation. This mutation has a thrombotic characteristic due to resistance to activated protein C (APC). Subacute lymphadenitis was an additional disruptive factor and led to thrombosis in the internal jugular vein. The patient received antibiotic treatment and Marcumar, which is planned to be given for a 3-month period.

Entities:  

Mesh:

Year:  2009        PMID: 19618128     DOI: 10.1007/s00106-009-1927-y

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  3 in total

Review 1.  Superior mediastinal and internal jugular venous thrombosis presenting to the otolaryngologist.

Authors:  Carmen De Casso; Sudip Ghosh; Michael Timms; Pradeep Morar
Journal:  J Laryngol Otol       Date:  2005-01       Impact factor: 1.469

2.  Factor V Leiden and the risk for venous thromboembolism in the adult Danish population.

Authors:  Klaus Juul; Anne Tybjaerg-Hansen; Peter Schnohr; Børge G Nordestgaard
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

Review 3.  Coagulation factor V and thrombophilia: background and mechanisms.

Authors:  Kenneth Segers; Björn Dahlbäck; Gerry A F Nicolaes
Journal:  Thromb Haemost       Date:  2007-09       Impact factor: 5.249

  3 in total
  1 in total

1.  [Thrombosed aneurysm of the subclavian vein].

Authors:  S Roos; F Bast; T Schrom
Journal:  HNO       Date:  2012-03       Impact factor: 1.284

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.